CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 261 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.35 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,514,898 | +4.9% | 899,478 | +20.6% | 0.01% | 0.0% |
| Q2 2023 | $10,023,297 | -25.6% | 745,781 | -8.2% | 0.01% | -27.3% |
| Q1 2023 | $13,466,375 | -13.8% | 812,206 | -3.3% | 0.01% | -15.4% |
| Q4 2022 | $15,629,599 | +60.3% | 840,301 | +10.5% | 0.01% | +44.4% |
| Q3 2022 | $9,753,000 | +120.2% | 760,174 | +20.3% | 0.01% | +125.0% |
| Q2 2022 | $4,430,000 | +54.7% | 631,904 | +83.0% | 0.00% | +100.0% |
| Q1 2022 | $2,863,000 | +91.9% | 345,348 | +56.7% | 0.00% | +100.0% |
| Q4 2021 | $1,492,000 | +68.6% | 220,424 | +32.0% | 0.00% | 0.0% |
| Q3 2021 | $885,000 | +79.9% | 167,041 | +95.3% | 0.00% | – |
| Q2 2021 | $492,000 | +151.0% | 85,544 | +101.6% | 0.00% | – |
| Q1 2021 | $196,000 | +56.8% | 42,430 | +13.5% | 0.00% | – |
| Q4 2020 | $125,000 | +20.2% | 37,399 | +7.3% | 0.00% | – |
| Q3 2020 | $104,000 | +19.5% | 34,866 | +86.0% | 0.00% | – |
| Q2 2020 | $87,000 | – | 18,747 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,378,584 | $3,116,000 | 2.30% |
| TANAKA CAPITAL MANAGEMENT INC | 147,993 | $298,000 | 0.90% |
| SOPHROSYNE CAPITAL LLC | 282,500 | $638,000 | 0.56% |
| Ghost Tree Capital, LLC | 200,000 | $452,000 | 0.27% |
| Orbimed Advisors | 1,895,000 | $4,283,000 | 0.05% |
| Financial Architects, Inc | 30,000 | $68,000 | 0.04% |
| Cowen Prime Services LLC | 43,550 | $98,000 | 0.04% |
| Rotella Capital Management, Inc. | 12,300 | $28,000 | 0.03% |
| FEDERATED HERMES, INC. | 3,267,000 | $7,384,000 | 0.02% |
| Baker Brothers Advisors | 569,853 | $1,288,000 | 0.02% |